Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: An immunohistochemical study

Endocrine Pathology

Volumn 22, Issue 1, 2011, Pages 24-30

  Diakatou, Evanthia ^a   Kaltsas, Gregory ^b   Tzivras, Michail ^b   Kanakis, George ^b   Papaliodi, Eugenia ^a   Kontogeorgos, George ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Dopamine receptors; Gastroenteropancreatic tumors; Immunohistochemistry; Somatostatin analogs; Somatostatin receptors

Indexed keywords

BIOLOGICAL MARKER; CHOLECYSTOKININ; CHROMOGRANIN A; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; GASTRIN; GHRELIN; GLUCAGON; INSULIN; LUTEINIZING HORMONE BETA SUBUNIT; PANCREAS POLYPEPTIDE; SEROTONIN; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A; SOMATOSTATIN RECEPTOR 2B; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABDOMINAL TUMOR; ARTICLE; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG TARGETING; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; RECEPTORS, DOPAMINE; RECEPTORS, SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79953292453     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-011-9149-8     Document Type: Article

References (33)

1. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198. (Pubitemid 29362641)
2. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450-482. Review.
3. de Herder WW, Hofland LJ, van der Lely AJ et al. Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 2003;10:451-458. (Pubitemid 38094881)
4. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptors 1-5 in 81 cases of gastrointestinal and pancreatic tumors. A correlative immunohistochemical and reverse transcriptase polymerase chain reaction. Virchows Arch 2002;440:461-475.
5. Reubi JC, Schaer JC, Waser B, et al. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-3459.
6. Reubi JC, Hacki WH, Lamberts SW. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 1987;65:1127-1134. (Pubitemid 18026846)
7. Corleto VD, Scopinaro F, Angeletti S et al. Somatostatin receptor localization of pancreatic endocrine tumors. World J Surg 1996;20:241-244. (Pubitemid 26069493)
8. Hofland LJ, Liu Q, Van Koetsveld PM et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999; 84: 775-780. (Pubitemid 29075720)
9. Ferone D, Arvigo M, Semino C et al. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am J Physiol Endocrinol Metab 2005; 289: E1044-E1050. (Pubitemid 43671055)
10. Florio T, Barbieri F, Spaziante R et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study Endocr Relat Cancer; 2008;15:583-596
11. Rindi G, Klöppel G, Couvelard A et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007; 451:757-762. (Pubitemid 47497934)
12. Klöppel G, Rindi G, Anlauf M et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(Suppl) 1:S9-S27. (Pubitemid 47283382)
13. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;458-511. (Pubitemid 38780668)
14. Volante M, Brizzi MP, Faggiano A. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007 Nov; 20(11):1172-1182. (Pubitemid 47609066)
15. Srirajaskanthan R, Watkins J, Marelli L et al. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology. 2009;89:308-314.
16. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor 2,3 and 5 in biopsy and surgical specimens of human lung tumors. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001;439:787-797.
17. Taniyama Y, Suzuki T, Mikami Y et al. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005;52:605-611. (Pubitemid 41609051)
18. Schultz S, Schultz S, Schmitt J, et al. Immunocytochemical detection of somatostatin receptors SST1, SST2A, SST2B and SST3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998;4:2047-2052. (Pubitemid 28415646)
19. Papotti M, Croce S, Macri L et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000;9:47-55.
20. Solcia E, Kloppel G & Sobin LH 2000 Histological typing of endocrine tumours. In World Health Organization International Histological Classification of Tumour, ed. 2 Berlin: Springer. pp. 61-68.
21. De Lellis R, Lloyd RV, Heitz PU & Eng C 2004 Pathology and Genetics of Tumours of Endocrine Organs (World Health Organization Classification of Tumours). Lyon: IARC Press.
22. Rindi G, Kloppel G, Alhman H et al TNM staging of foregut (neuro)endocrine tumours: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401. (Pubitemid 44451313)
23. Rindi G, Kloppel G, Coulevard At et al TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.) Virchows Arch.2007 Oct;451 (4):757-762
24. Lemmer K, Ahnert-Hilger G, Höpfner M et al. Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci. 2002;71:667-678. (Pubitemid 34628828)
25. O'Toole D, Saveanu A, Couvelard A et al. The analysis of quantitative expression of somatostatin and dopamine expression in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol. 2006;155:849-857. (Pubitemid 46040624)
26. Thodou E, Kontogeorgos G, Theodossiou D et al. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol. 2006;59:274-279. (Pubitemid 43344889)
27. Papotti M, Kumar U, Volante M et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 2001;54:641-649. (Pubitemid 34208908)
28. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24:389-427. (Pubitemid 37056239)
29. Oda Y, Tanaka Y, Naruse T, et al. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 2002;36:690-694. (Pubitemid 35002270)
30. Weckbecker G, Briner U, Lewis I. SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like Growth Factor-I axis in rats, primates and dogs. Endocrinology 2002;143:4123-4130. (Pubitemid 35244391)
31. Hofland LJ and Lamberts SW: The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr Rev 2003;24:28-47.
32. Rocheville M, Lange DC, Kumar U et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000; 288:154-157 (Pubitemid 30203051)
33. Kwekkeboom DJ, Kam BL, van Essen M et al: Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;29:17: R53-R73.